미국 · 보도자료 · Cullinan Therapeutics, Inc. · 2026-10-08 11:00
급성 골수성 백혈병 치료제 CLN-049, 임상 2상 첫 환자 투약
CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that the first patient has been dosed in its pivotal Phase 2 study of CLN-049, a novel, investigational FLT3 T cell
Cullinan Therapeutics, Inc. 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
